中國生物科技服務(08037.HK)全年營業額達6.56億港元 同比大幅增加逾10倍
格隆匯 3 月 24日丨中國生物科技服務(08037.HK)發佈截至2020年12月31日止年度全年業績公吿，2020年年度，集團錄得營業額約6.56億港元，較2019年同期大幅增加約10.07倍。有監於新型冠狀病毒疫症在世界各地迅速傳播，各行各業的業務營運及整體環球經濟均受到巨大影響。為把握需求轉為以COVID-19測試服務為主的市場份額，集團已經在香港設立一間實驗室以及一間有16個氣膜的額外臨時實驗室，為香港市民提供COVID-19檢測服務。在香港於7月中旬出現的第三波新冠肺炎疫情，集團為私家診所、公司及政府客户以及個人提供COVID-19檢測服務。因此，2020年年度，透過策略性發展及市場推廣及宣傳活動，來自提供醫學實驗室檢測服務及健康檢查服務分部的收入出現大幅增加。
2020年年度，集團錄得毛利約3.39億港元，較2019年年度增加約3.17億港元。此外，2020年年度的毛利率約為51.71%，較2019年年度的毛利率約37.78%上升約13.93個百分點。毛利率上升由於醫學實驗室檢測服務及健康檢查服務分部的營業額出現大幅上升。
2020年年度，集團錄得溢利淨額約1.68億港元(2019年年度：虧損淨額約1.07億港元)。由2019年年度的虧損淨額扭轉為2020年年度的溢利淨額，主要是由於以下各項所致：(i)香港於7月中旬出現第三波新冠肺炎疫情，導致對COVID-19檢測服務的需求大幅增加；(ii)集團為在普及社區檢測計劃為香港市民提供COVID-19檢測服務的參與者之一；及(iii)透過策略性發展及市場推廣及宣傳活動，以致提供醫學實驗室檢測服務及健康檢查服務分部的收入及毛利出現強勁增長。
公吿表示，集團有信心在新的一年裏，迎接挑戰，把握機遇，積極探索將檢測業務進行多元化轉型；儘快開展已經獲得臨牀批件的CAR-T產品的一期臨牀試驗，同時推進針對實體瘤的CAR-T產品以及通用CAR-T產品的研發和臨牀批件申報準備工作；引進具有潛力的海外項目，深化在大灣區的醫療健康產業佈局，致力於成為國際先進的生物醫療創新平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
